Despite intense research, there’s been much confusion regarding the exact role of a protein in a critical cancer-linked pathway. On one hand, the protein is described as a cell proliferation inhibitor, on the other, a cell proliferation activator, a duality that has caused a great deal of scientific head scratching. Now scientists have solved the conundrum, uncovering the regulatory machinery underlying the function of a protein, called angiomotin.